Evidence map›Paper›PMID 35264114›Full record

Trial reportBMC cardiovascular disorders2022

Common genetic variants do not predict recurrent events in coronary heart disease patients.

P L Thompson, J Hui, J Beilby, L J Palmer, G F Watts, M J West, A Kirby, S Marschner, R J Simes, D R Sullivan and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cardiovascular disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

P L ThompsonHeart and Vascular Research Institute, Harry Perkins Institute of Medical Research, Faculty of Health and Medical Sciences, Sir Charles Gairdner Hospital, University of Western Australia, Hospital Ave, Perth, Nedlands, WA, 6009, Australia. peter.thompson@health.wa.gov.au.
J HuiHealth Department of Western Australia, PathWest, Perth, Australia.
J BeilbyHealth Department of Western Australia, PathWest, Perth, Australia.
L J PalmerSchool of Public Health, University of Adelaide, Adelaide, Australia.
G F WattsFaculty of Health and Medical Sciences, University of Western Australia, Perth, Australia.
M J WestFaculty of Medicine and Biomedical Sciences, University of Queensland, Brisbane, Australia.
A KirbyNHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
S MarschnerNHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
R J SimesNHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
D R SullivanDepartment of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, Australia.
H D WhiteGreen Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
R StewartGreen Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
A M TonkinSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is unclear whether genetic variants identified from single nucleotide polymorphisms (SNPs) strongly associated with coronary heart disease (CHD) in genome-wide association studies (GWAS), or a genetic risk score (GRS) derived from them, can help stratify risk of recurrent events in patients with CHD.

methodsStudy subjects were enrolled at the close-out of the LIPID randomised controlled trial of pravastatin vs placebo. Entry to the trial had required a history of acute coronary syndrome 3-36 months previously, and patients were in the trial for a mean of 36 months. Patients who consented to a blood sample were genotyped with a custom designed array chip with SNPs chosen from known CHD-associated loci identified in previous GWAS. We evaluated outcomes in these patients over the following 10 years.

resultsOver the 10-year follow-up of the cohort of 4932 patients, 1558 deaths, 898 cardiovascular deaths, 727 CHD deaths and 375 cancer deaths occurred. There were no significant associations between individual SNPs and outcomes before or after adjustment for confounding variables and for multiple testing. A previously validated 27 SNP GRS derived from SNPs with the strongest associations with CHD also did not show any independent association with recurrent major cardiovascular events.

conclusionsGenetic variants based on individual single nucleotide polymorphisms strongly associated with coronary heart disease in genome wide association studies or an abbreviated genetic risk score derived from them did not help risk profiling in this well-characterised cohort with 10-year follow-up. Other approaches will be needed to incorporate genetic profiling into clinically relevant stratification of long-term risk of recurrent events in CHD patients.

Indexed as

Coronary DiseaseGenome-Wide Association StudyGenetic Predisposition to DiseaseGenotypeHumansPolymorphism, Single NucleotideRisk FactorsCoronary heart diseaseGenetic risk scoresGenetic variantGenome-wide association studiesGWASLack of predictionLIPID studyOmnigenic risk scoresPolygenic risk scores

Identifiers

PMID35264114
PMCPMC8908687

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.